Last reviewed · How we verify

argenx SE — Portfolio Competitive Intelligence Brief

argenx SE (ARGX) pipeline: 2 marketed, 0 filed, 3 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ARGX (NASDAQ) 2 marketed 0 filed 3 Phase 3 5 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vyvgart EFGARTIGIMOD ALFA marketed Endoglycosidase [EPC] IgG receptor FcRn large subunit p51 Immunology 2021-01-01
Efgartigimod PH20 SC Efgartigimod PH20 SC marketed FcRn antagonist Neonatal Fc receptor (FcRn) Immunology
ARGX-113 ARGX-113 phase 3 FcRn inhibitor FcRn (neonatal Fc receptor) Immunology
efgartigimod IV efgartigimod IV phase 3 Monoclonal antibody FcRn Immunology
Empasiprubart IV Empasiprubart IV phase 3 FcRn antagonist FcRn (neonatal Fc receptor) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 2 shared drug classes
  2. Alexion Pharmaceuticals, Inc. · 1 shared drug class
  3. Baxalta now part of Shire · 1 shared drug class
  4. Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
  7. AgeneBio · 1 shared drug class
  8. Adrienne G. Waks · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for argenx SE:

Cite this brief

Drug Landscape (2026). argenx SE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/argenx. Accessed 2026-05-14.

Related